^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Avastin (bevacizumab)

    i
    Other names: R 435, RG435, R435, rhuMAb-VEGF, RO-4876646, RG 435, RO4876646, R-435, RG-435, RO 4876646
    Company:
    Roche
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    22h
    A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=190, Recruiting, Taizhou Hanzhong biomedical co. LTD | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2026 --> Jun 2026
    Enrollment open • Trial primary completion date • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • Puyouheng (pucotenlimab)
    23h
    AMBITION: A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P3, N=281, Completed, Japanese Foundation for Cancer Research | Trial completion date: Sep 2025 --> Mar 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • HER-2 negative
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel
    24h
    ML41701: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. (clinicaltrials.gov)
    P2, N=22, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    1d
    NIBCUN: Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • carboplatin • Tyvyt (sintilimab) • pemetrexed
    1d
    BEATcc: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (clinicaltrials.gov)
    P3, N=410, Completed, Grupo Español de Investigación en Cáncer de Ovario | Active, not recruiting --> Completed
    Trial completion
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • paclitaxel
    2d
    TROY: Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy (clinicaltrials.gov)
    P2, N=116, Recruiting, Yonsei University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki)
    2d
    Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients (clinicaltrials.gov)
    P2/3, N=156, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2028 --> Dec 2029
    Trial completion date • pMMR
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab)
    2d
    Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov)
    P1/2, N=85, Recruiting, Mayo Clinic | Trial completion date: Feb 2028 --> Aug 2029 | Trial primary completion date: Aug 2027 --> Aug 2029
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2d
    A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov)
    P1, N=330, Recruiting, Pfizer | Trial completion date: Sep 2028 --> Jan 2029 | Trial primary completion date: Sep 2027 --> Jan 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab)
    3d
    Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update. (PubMed, J Clin Oncol)
    Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    3d
    Multi-Omics and Machine Learning-Uncovered FLT1-Mediated Epithelial-Endothelial Crosstalk in Cellular Senescence Driving Clear Cell Renal Cell Carcinoma Malignancy. (PubMed, FASEB J)
    For patients with high FLT1 expression, a combination therapy targeting this network-screened via molecular docking and dynamics simulations-may improve prognosis. This includes FLT1 inhibitors (Sorafenib, Regorafenib, Lenvatinib), supplemented by AKT1 inhibitors (Capivasertib) and VEGFA inhibitors (Bevacizumab) to suppress FLT1-associated malignant cell populations.
    Journal • IO biomarker
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • FLT1 (Fms-related tyrosine kinase 1)
    |
    Avastin (bevacizumab) • sorafenib • Lenvima (lenvatinib) • Stivarga (regorafenib) • Truqap (capivasertib)